Table 2

Squalestatin reduces co-localisation between MoPrP105-132 and cPLA2/COX-1. The percentage of MoPrP105-132 that co-localised with the signalling enzymes cPLA2 or COX-1 in untreated neuroblastoma cells and cells treated for 24 hours with either 1 μM squalestatin or 2 Hexa-PAF, 5 minutes after the addition of peptide. Values shown are mean ± SD, calculated after counting a minimum of 3 cells.

Co-localisation with MoPrP105-132

Drug Treatments


Untreated

Squalestatin

Hexa-PAF


cPLA2

38% ± 7

13% ± 4

22% ± 6

COX-1

70% ± 5

5% ± 5

13% ± 3


Wilson et al. BMC Neuroscience 2007 8:99   doi:10.1186/1471-2202-8-99

Open Data